Code intelligence

FDA-NDA217686 reimbursement alerts

Policy changes, MAC LCD updates, and CMS guidance matched to code FDA-NDA217686.

Elevated code risk

Signal breakdown

1 shown · 1 total in platform

Risk: Elevated

Critical

High

100%

Routine

Low

New this month

alerts added in last 30 days

Effective soon

—

no upcoming deadlines

FDA Approval: TRYVIO (APROCITENTAN) — Type 1 - New Molecular Entity

Policy FDA-NDA217686 · Cardiology

High

Tryvio (aprocitentan) is an oral endothelin receptor antagonist approved for resistant hypertension, billing through Medicare Part D as a self-administered tablet. As an oral outpatient medication, it

View alert

Audit documentation

Building an audit file that includes FDA-NDA217686?

The Tripwire Audit Pack exports 12 months of Cardiology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.

Get the Cardiology audit pack — $349One-time purchase · not a subscription